Patents by Inventor Masanobu Kirita

Masanobu Kirita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230151057
    Abstract: Provided is a lactic acid bacteria growth promoter which has a growth promotion effect on lactic acid bacteria. The lactic acid bacteria growth promoter includes at least one peptide selected from the group consisting of: a first peptide having a total number of residues of not more than 9 and comprising a hydrophobic amino acid residue at the C-terminus; and a second peptide having a total number of residues of not more than 9. The ratio of the total number of hydrophobic amino acid residues and proline residues to the total number of residues is not less than 2/3.
    Type: Application
    Filed: June 1, 2021
    Publication date: May 18, 2023
    Applicant: Asahi Group Holdings, Ltd.
    Inventors: Naoto UCHIDA, Masanobu KIRITA
  • Patent number: 7879586
    Abstract: A gene encoding a methylated catechin synthase that can effectively synthesize methylated catechins having high antiallergic activity. The gene encoding a methylated catechin synthase contains at least one nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3 and 5.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: February 1, 2011
    Assignees: Incorporated Administrative Agency National Agriculture and Food Research Organization, Asahi Breweries, Ltd.
    Inventors: Mari Yamamoto, Masanobu Kirita, Manabu Sami, Mitsuo Ikeda
  • Publication number: 20100324312
    Abstract: A novel methylated catechin is provided which has stronger antiallergic activity than conventionally known methylated catechins such as epigallocatechin-3-O-(3-O-methyl)gallate and epigallocatechin-3-O-(4-O-methyl)gallate. The epigallocatechin-3-O-gallate derivative is represented by the chemical formula I: (wherein R1 to R6 are each a hydrogen atom or a methyl group, and at least three of R1 to R6 are methyl groups) or an isomer thereof.
    Type: Application
    Filed: January 21, 2008
    Publication date: December 23, 2010
    Applicants: INCORPORATED ADMINSTRATIVE AGENCY NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION, ASAHI BREWERIES, LTD.
    Inventors: Mari Yamamoto, Masanobu Kirita, Daiki Honma, Toyokazu Yokota
  • Patent number: 7612115
    Abstract: The present invention has an object to provide an antibacterial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when new quinolone antibacterial agents such as ofloxacin as the active ingredient and can be retained at the administration site for a long time by virtue of rapid viscosity increase after administration in spite of their being liquid at administration and thereby attain high availability of pharmaceutical agent. The present invention relates to an antibacterial aqueous pharmaceutical composition which comprises: 2.8 to 4 w/v % of methylcellulose, the 2 w/v % aqueous solution of which has a viscosity of 12 mPa·s or below at 20° C.; 1.5 to 2.3 w/v % of citric acid; 2 to 4 w/v % of polyethylene glycol; and 0.1 to 0.5 w/v % of ofloxacin.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: November 3, 2009
    Assignee: Wakamoto Pharmaceutical Co., Ltd.
    Inventors: Hidekazu Suzuki, Takahiro Wada, Masanobu Kirita, Masanobu Takeuchi
  • Publication number: 20090205068
    Abstract: The present invention relates to: a method for producing a transgenic plant expressing miraculin, comprising introducing a miraculin gene into a useful plant that can be easily produced and cultivated throughout the year using plant molecular breeding technology; a transgenic plant expressing miraculin, which is produced by the method; and the use thereof. The present invention also relates to a food additive, a food or drink, or an antidiabetic drug, which contains miraculin that is produced by the transgenic plant.
    Type: Application
    Filed: August 4, 2005
    Publication date: August 13, 2009
    Applicants: Hiroshi EZURA, INPLANTA INNOVATIONS INC
    Inventors: Hiroshi Ezura, Hyeon-Jin Sun, Masanobu Kirita, Takanari Ichikawa, Nobuyo Nishizaki
  • Publication number: 20080318272
    Abstract: A gene encoding a methylated catechin synthase that can effectively synthesize methylated catechins having high antiallergic activity. The gene encoding a methylated catechin synthase contains at least one nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3 and 5.
    Type: Application
    Filed: November 14, 2005
    Publication date: December 25, 2008
    Inventors: Mari Yamamoto, Masanobu Kirita, Manabu Sami, Mitsuo Ikeda
  • Publication number: 20060172969
    Abstract: The present invention has an object to provide an antibacterial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when new quinolone antibacterial agents such as ofloxacin as the active ingredient and can be retained at the administration site for a long time by virtue of rapid viscosity increase after administration in spite of their being liquid at administration and thereby attain high availability of pharmaceutical agent. The present invention relates to an antibacterial aqueous pharmaceutical composition which comprises: 2.8 to 4 w/v % of methylcellulose, the 2 w/v % aqueous solution of which has a viscosity of 12 mPa·s or below at 20° C.; 1.5 to 2.3 w/v % of citric acid; 2 to 4 w/v % of polyethylene glycol; and 0.1 to 0.5 w/v % of ofloxacin.
    Type: Application
    Filed: March 13, 2006
    Publication date: August 3, 2006
    Applicant: Wakamoto Pharmaceutical Co., Ltd.
    Inventors: Hidekazu Suzuki, Takahiro Wada, Masanobu Kirita, Masanobu Takeuchi
  • Publication number: 20030194441
    Abstract: The present invention has an object to provide an antibacterial aqueous pharmaceutical composition and an aqueous pharmaceutical composition which have a sufficiently low gelation temperature even when new quinolone antibacterial agents such as ofloxacin as the active ingredient and can be retained at the administration site for a long time by virtue of rapid viscosity increase after administration in spite of their being liquid at administration and thereby attain high availability of pharmaceutical agent.
    Type: Application
    Filed: June 2, 2003
    Publication date: October 16, 2003
    Inventors: Hidekazu Suzuki, Takahiro Wada, Masanobu Kirita, Masanobu Takeuchi